

Appendix A: Key to Acronyms

3TC	lamivudine
3TC/ZDV	lamivudine + zidovudine
ABC	abacavir
ABC/3TC	abacavir + lamivudine
ABC/3TC/ZDV	abacavir + lamivudine + zidovudine
ACTG	AIDS Clinical Trials Group
AIDS	acquired immune deficiency syndrome
ALT	alanine aminotransferase
APV	amprenavir
ART	antiretroviral therapy
ART-CC	ART Cohort Collaboration
ARV	antiretroviral
AST	aspartate aminotransferase
ATV	atazanavir
ATV/r	atazanavir/ritonavir or ritonavir-boosted atazanavir
AUC	area under the curve
AV	atrioventricular
bDNA	branched DNA
BID	twice a day
BMD	bone mineral density
BUN	blood urea nitrogen
CAPD	chronic ambulatory peritoneal dialysis
CBC	complete blood count
CCB	calcium channel blocker
CDC	Centers for Disease Control and Prevention
CI	confidence interval
C _{max}	maximum concentration or peak concentration
CME	continuing medical education
C _{min}	minimum concentration or trough concentration
CMV	cytomegalovirus
CNS	central nervous system
CPK	creatine phosphokinase
CrCl	creatinine clearance
CVD	cardiovascular disease
CYP	cytochrome P
d4T	stavudine
D:A:D	Data Collection on Adverse Events of Anti-HIV Drugs Study
ddC	zalcitabine
ddI	didanosine
DHHS	Department of Health and Human Services
DILI	drug-induced liver injury
DLV	delavirdine
DM	diabetes mellitus
D/M	dual or mixed (tropic)
DMPA	depot medroxyprogesterone
DOT	directly observed therapy
DRV	darunavir
DRV/r	darunavir/ritonavir or ritonavir-boosted darunavir

DXA	dual-energy x-ray absorptiometry
EBV	Epstein-Barr virus
EC	enteric coated
ECG	electrocardiogram
EFV	efavirenz
EFV/FTC/TDF	efavirenz + emtricitabine + tenofovir disoproxil fumarate
EIA	enzyme immunoassay
ETR	etravirine
FDA	Food and Drug Administration
FI	fusion inhibitor
FPV	fosamprenavir
FPV/r	fosamprenavir/ritonavir or ritonavir-boosted fosamprenavir
FTC	emtricitabine
FTC/TDF	emtricitabine + tenofovir disoproxil fumarate
GAZT	AZT glucuronide
GHB	gamma hydroxybutyrate
GI	gastrointestinal
HAV	hepatitis A virus
HBeAg	hepatitis B e antigen
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HD	hemodialysis
HDL	high-density lipoprotein
HELLP	hemolysis, elevated liver enzymes, low platelet count (syndrome)
HHS	Health and Human Services
HHV	human herpes virus
HHV-8	human herpes virus 8
HIV	human immunodeficiency virus
HIV-1	human immunodeficiency virus type 1
HIV-2	human immunodeficiency virus type 2
HIVAN	HIV-associated nephropathy
HPV	human papilloma virus
HR	hazard ratio
HRSA	Health Resource Services Administration
hsCRP	high sensitivity C-reactive protein
HSR	hypersensitivity reaction
HTLV	human T-cell leukemia virus
HTLV-1	human T-cell leukemia virus type 1
HTLV-2	human T-cell leukemia virus type 2
IAS-USA	International AIDS Society-USA
IC	inhibitory concentration
IDU	illicit drug user
IDV	indinavir
IDV/r	indinavir/ritonavir or ritonavir-boosted indinavir
IFN- γ	interferon-gamma
IGRA	interferon-gamma release assay
IL-2	interleukin-2
IL-6	interleukin-6
IL-7	interleukin-7
IND	investigational new drug

INH	isoniazid
INR	international normalized ratio
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IRB	Institutional Review Board
IRIS	immune reconstitution inflammatory syndrome
LDL	low-density lipoprotein
LPV	lopinavir
LPV/r	lopinavir/ritonavir or ritonavir-boosted lopinavir
LTBI	latent tuberculosis infection
MAC	<i>Mycobacterium avium</i> complex
MDMA	methyleneoxyamphetamine
MDRD	modification of diet in renal disease (equation)
MHC	major histocompatibility complex
MI	myocardial infarction
msec	milliseconds
MSM	men who have sex with men
MTB	<i>Mycobacterium tuberculosis</i>
MTCT	mother-to-child transmission
MVC	maraviroc
NA-ACCORD	The North American AIDS Cohort Collaboration on Research and Design
NFV	nelfinavir
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NVP	nevirapine
OAR	Office of AIDS Research
OARAC	Office of AIDS Research Advisory Council
PAH	pulmonary arterial hypertension
PCP	<i>Pneumocystis jiroveci</i> pneumonia
PDE5	phosphodiesterase type 5
PI	protease inhibitor
PK	pharmacokinetic
PMTCT	prevention of mother-to-child transmission
PO	by mouth
PPI	proton pump inhibitor
PR	protease (gene)
PT	prothrombin time
QTc	QT corrected for heart rate
RAL	raltegravir
RPV	rilpivirine
RT	reverse transcriptase (gene)
RT-PCR	reverse transcriptase-polymerase chain reaction
RTV	ritonavir
SJS	Stevens-Johnson syndrome
SPT	skin patch test
SQV	saquinavir
SQV/r	saquinavir/ritonavir or ritonavir-boosted saquinavir

STI	sexually transmitted infection
t _½	half-life
T-20	enfuvirtide
TAM	thymidine analogue mutation
TB	tuberculosis
TCA	tricyclic antidepressant
TDF	tenofovir disoproxil fumarate or tenofovir
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrosis
TG	triglyceride
TID	three times a day
TPV	tipranavir
TPV/r	tipranavir/ritonavir or ritonavir-boosted tipranavir
TST	tuberculin skin test
UDP	uridine diphosphate
UGT1A1	uridine diphosphate glucuronosyltransferase 1A1
VPA	valproic acid
WBC	white blood cell
WHO	World Health Organization
WITS	Women and Infants Transmission Study
ZDV	zidovudine